Promising to be an alternative to antibiotics, antimicrobial peptides have huge market space in the future

"Pharmaceutical Network Market Analysis" antimicrobial peptides are a class of small peptide molecules with antibacterial activity, because of its rapid sterilization and difficult to lead to microbial resistance worldwide attention, can be used for the development of new antimicrobial candidate molecules.
are an important part of multicellular bioimmune defense and are being developed as anti-infectants, according to researchers at the University of California, California.
in the future antimicrobial peptide drug market space is huge.
According to its introduction, there are currently 11.4 million people with "diabetic foot", of which nearly 1/3 have had their limbs amputated;
"PL-5 is an innovative antimicrobial peptide drug entering the clinical trial stage in China, and also an innovative drug for peptides used in the field of anti-infection at home and abroad.
" Chen Yuxin said that the clinical application of PL-5 is located in diabetic foot, hemorrhoids, extensive burns burns, trauma, surgery and other causes of open wound infection, including stubborn drug-resistant bacteria caused by infection.
It is known that, unlike traditional antibiotics, antimicrobial peptides are a class of peptides composed of amino acids, with rapid sterilization and difficult to lead to microbial resistance and other characteristics, is a good antibacterial candidate molecules.
results show that after feeding bacteria with less than lethal amount of antibiotics, 4 to 5 generations of bacteria will develop resistance to antibiotics, and with the same dose of antibacterial peptides to feed bacteria, until 32 generations later, increase the dose of antimicrobial peptides, bacteria will still be killed by antimicrobial peptides, will not produce resistance.
of antibiotic resistance is becoming more and more serious, and the study of new anti-infective drugs has become one of the urgent medical problems.
And antimicrobial peptides have broad-spectrum antibacterial activity, target strains are not prone to resistant mutations, bacteria (including certain drug-resistant pathogens) have a strong lethal effect, it is believed that antimicrobial peptides are expected to become an ideal alternative to antibiotics.
it is worth noting that research on antimicrobial peptide drugs has been going on for about 40 years, but no heavy-duty drugs have yet appeared.
industry said: "The development cycle and technical difficulty of antimicrobial peptide drugs is unimaginable.
hope that more people will realize the importance of antimicrobial peptide drugs, support or invest in antimicrobial peptide drug research and development.
is understood to have identified antibiotic resistance as one of the great threats to global health, food safety and development today, and antimicrobial peptide drug research has been supported, with China's National Action Plan to Curb Bacterial Resistance (2016-2020) clearly relevant to increase antimicrobial-related research and development to support the development of new anti-infective drugs.
Such as the antibacterial peptide project of Pllei Pharmaceuticals has been supported, has been included in the Ministry of Science and Technology and the Health planning committee "science and technology-based small and medium-sized enterprises innovation fund" project, "12th Five-Year Plan" "13th Five-Year Plan" major new drug creation projects.
antibacterial peptides have the advantages of rapid sterilization, broad antibacterial spectrum, small toxic side effects and no immunogenicity.
, because of its special bactericidal process, inhibited or killed pathogenic microorganisms do not produce resistant strains, and do not weaken the role of killing bacteria due to drug resistance.
, antimicrobial peptides are an ideal alternative to antibiotics.
the future antimicrobial peptide drug market space is huge, in order to better promote the development of antimicrobial peptide drugs, it is necessary to work together.
To this end, many industry people put efforts to this end, such as the industry believes that the key problem of transforming antimicrobial peptides is to maintain their existing antibacterial activity, and greatly reduce toxicity, enhance stability, while reducing the length of the peptide chain to achieve low costs; And increase specificity, this aspect comes from the characteristics of natural antimicrobial peptides themselves, on the other hand, depending on the nature of different bacteria themselves, such as Glollath-negative bacteria and Glollath-positive bacteria in the cell wall and cell membrane is very different, according to this characteristic, for different types of bacteria, through design modification to optimize antimicrobial peptides.